Companies › iLeukon Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jun 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ILKN421H | – | Phase 2 | Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07452224 | ILKN421H | Phase 2 | Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Oncology | Jun 2029 |
No annotated target.
–
Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.